NO953862D0 - Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt - Google Patents

Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt

Info

Publication number
NO953862D0
NO953862D0 NO953862A NO953862A NO953862D0 NO 953862 D0 NO953862 D0 NO 953862D0 NO 953862 A NO953862 A NO 953862A NO 953862 A NO953862 A NO 953862A NO 953862 D0 NO953862 D0 NO 953862D0
Authority
NO
Norway
Prior art keywords
contents
actin
respiratory tract
viscosity
pathological
Prior art date
Application number
NO953862A
Other languages
English (en)
Norwegian (no)
Other versions
NO953862L (no
Inventor
Thomas P Stossel
Stuart Lind
Paul A Janmey
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO953862L publication Critical patent/NO953862L/no
Publication of NO953862D0 publication Critical patent/NO953862D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO953862A 1993-04-02 1995-09-29 Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt NO953862D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/042,247 US5464817A (en) 1990-04-11 1993-04-02 Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
PCT/US1994/003667 WO1994022465A1 (en) 1993-04-02 1994-04-04 Method for reducing the viscosity of pathological mucoid airway contents in the respiratoy tract

Publications (2)

Publication Number Publication Date
NO953862L NO953862L (no) 1995-09-29
NO953862D0 true NO953862D0 (no) 1995-09-29

Family

ID=21920852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953862A NO953862D0 (no) 1993-04-02 1995-09-29 Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt

Country Status (17)

Country Link
US (2) US5464817A (es)
EP (1) EP0692970B1 (es)
JP (2) JPH08510998A (es)
KR (1) KR100308679B1 (es)
CN (1) CN1107521C (es)
AT (1) ATE182790T1 (es)
AU (1) AU695033B2 (es)
BR (1) BR9405856A (es)
CA (1) CA2159205A1 (es)
DE (1) DE69419907T2 (es)
DK (1) DK0692970T3 (es)
ES (1) ES2135576T3 (es)
GB (1) GB2293102B (es)
GR (1) GR3031753T3 (es)
NO (1) NO953862D0 (es)
SG (1) SG49574A1 (es)
WO (1) WO1994022465A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
BR9510323A (pt) * 1995-02-24 1997-11-11 Genentech Inc Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
PT854927E (pt) * 1995-10-10 2008-09-08 Genentech Inc Variantes da adnase i humana
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
DE69716460T2 (de) 1996-12-04 2003-06-26 Renovo Ltd Wundheilung und behandlung von fibrose
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
BR0207725A (pt) * 2001-12-28 2004-03-23 Daiichi Suntory Biomedical Res Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos
WO2005004904A1 (fr) * 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PL1694342T3 (pl) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
CN1980694B (zh) * 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
WO2006017816A2 (en) * 2004-08-06 2006-02-16 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
ES2651619T3 (es) * 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas
ATE513557T1 (de) * 2006-11-28 2011-07-15 Cls Therapeutics Ltd Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens
WO2008101084A2 (en) * 2007-02-15 2008-08-21 National Jewish Medical And Research Center Methods and compositions for the disruption of biofilms
PL2708603T3 (pl) 2008-01-25 2017-12-29 Beth Israel Deaconess Medical Ct Inc Diagnostyczne i terapeutyczne zastosowania gelsoliny w niewydolności nerek
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN108289932A (zh) 2015-05-22 2018-07-17 D·D·格恩金 胞外dna作为神经变性的治疗靶点
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
WO1991015770A1 (en) * 1990-04-11 1991-10-17 The General Hospital Corporation Therapeutic uses of actin-binding compounds
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis

Also Published As

Publication number Publication date
EP0692970B1 (en) 1999-08-04
DK0692970T3 (da) 1999-12-06
AU6625094A (en) 1994-10-24
NO953862L (no) 1995-09-29
BR9405856A (pt) 1996-03-05
KR100308679B1 (ko) 2001-11-30
DE69419907T2 (de) 1999-12-09
CN1107521C (zh) 2003-05-07
AU695033B2 (en) 1998-08-06
JPH08510998A (ja) 1996-11-19
DE69419907D1 (de) 1999-09-09
GB2293102B (en) 1996-10-09
GR3031753T3 (en) 2000-02-29
CA2159205A1 (en) 1994-10-13
ATE182790T1 (de) 1999-08-15
ES2135576T3 (es) 1999-11-01
EP0692970A1 (en) 1996-01-24
SG49574A1 (en) 1998-06-15
JP2001302537A (ja) 2001-10-31
GB2293102A (en) 1996-03-20
GB9520020D0 (en) 1995-12-06
CN1122108A (zh) 1996-05-08
US5656589A (en) 1997-08-12
US5464817A (en) 1995-11-07
WO1994022465A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
NO953862D0 (no) Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
ES2160704T3 (es) Tratamiento del sindrome de insensibilidad parcial a la hormona de crecimiento.
DE69130289D1 (de) Therapeutische verwendung von actin-bindenden verbindungen
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
BR9809951A (pt) Método para tratamento da obesidade
ATE233096T1 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
BR9607601A (pt) Uso de ácido hialurÈnico para o tratamento de cistite intersticial
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
PT782630E (pt) Gene da doenca poliquistica do rim
DK0914148T3 (da) Behandling af partielt væksthormonoverfølsomhedssyndrom
DK0839157T3 (da) Colostrum-afledt vækstfaktor
NZ334762A (en) Human DNase I variants having binding affinity to actin
BR9510323A (pt) Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
Brancaccio et al. Purification and partial characterization of a new 85 KDa amyloidosis-related protein in chronic hemodialysis
Kurowski et al. Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies
BR0011178A (pt) Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma
BR9713355A (pt) Proteìna de ligação à lactoferrina d streptococcus uberis
Shaw et al. The effect of gastric surgery on intact neurotensin (NT) response to a fatty meal
Kobori et al. Immunohistological observation of the Cochlea Using the Serum from the Patient with Relapsing Polychondritis
Meisels et al. Serum ferritin level in hemodialysis patients
Eman Evaluation of bilevel postive airway pressure ventilation in acute exacerbations of chronic obstructive pulmonary disease
NO952608L (no) Derivatiserte kalsitoniner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application